Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx)

Read the full 132 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE